Transforming fertility treatment
Science Park company VivoPlex Group has closed its Series A fundraising round at £3 million – funds that will be used in the clinical development of the company’s intra-uterine monitoring product, CE marking and development of a finalised production-ready device.
It has also appointed Joanna Smart as CEO (formerly COO) and established an international Scientific Advisory Board. Led by Professor Macklon, Medical Director of the London Women’s Clinic and Professor of Obstetrics and Gynaecology at the University of Copenhagen, the international board comprises fertility and embryology experts based in Auckland, London, Melbourne and San Francisco.
Ms Smart, commented: “The Scientific Advisory Board will be an invaluable resource for us as our intra-uterine sensor moves through the next stages of clinical and product development. Their scientific and clinical expertise, combined with their global networks of key opinion leaders, will contribute significantly to VivoPlex's progress. I'd like to welcome the five members of the Scientific Advisory Board and thank them for their commitment to the company.'
VivoPlex Group is a leader in real time and accurate intra-uterine monitoring for the optimisation of fertility treatment and uterine health. Its product is in development as the first insertable wireless device for the measurement of key uterine parameters – oxygen concentration, pH and temperature – in vivo. Better understanding of these levels in humans in real time and over the long term should enable improvement of the success rate of fertility treatment, currently 25-30%.